Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.

Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S.

Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.

PMID:
31395600
2.

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.

Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM.

Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25555. [Epub ahead of print] No abstract available.

PMID:
31179561
3.

Genomic profiling and predicting treatment response in acute myeloid leukemia.

Isidori A, Loscocco F, Curti A, Amadori S, Visani G.

Pharmacogenomics. 2019 May;20(7):467-470. doi: 10.2217/pgs-2018-0202. No abstract available.

4.

Cylindrical Layered Bone Scaffolds with Anisotropic Mechanical Properties as Potential Drug Delivery Systems.

Di Filippo MF, Amadori S, Casolari S, Bigi A, Dolci LS, Panzavolta S.

Molecules. 2019 May 19;24(10). pii: E1931. doi: 10.3390/molecules24101931.

5.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2019 May 16. pii: haematol.2019.221333. doi: 10.3324/haematol.2019.221333. [Epub ahead of print]

6.

Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931- July 15, 2018.

Amadori S, Arcese W, Avvisati G, Gale RP, Lo-Coco F.

Leukemia. 2019 Feb;33(2):285-286. doi: 10.1038/s41375-018-0352-1. No abstract available.

PMID:
30635628
7.

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.

Efficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F.

Leukemia. 2019 Jul;33(7):1598-1607. doi: 10.1038/s41375-018-0325-4. Epub 2018 Dec 20.

PMID:
30573776
8.

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Albano F, Lefrère F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Haematologica. 2019 Jun;104(6):1168-1175. doi: 10.3324/haematol.2018.204826. Epub 2018 Dec 6.

9.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
10.

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach.

Isidori A, Loscocco F, Ciciarello M, Corradi G, Lecciso M, Ocadlikova D, Parisi S, Salvestrini V, Amadori S, Visani G, Curti A.

Cancers (Basel). 2018 Jun 22;10(7). pii: E211. doi: 10.3390/cancers10070211. Review.

11.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Oct;97(10):1785-1795. doi: 10.1007/s00277-018-3396-4. Epub 2018 Jun 20.

12.

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A.

Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7. Review.

PMID:
29495904
13.

Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.

Ottone T, Alfonso V, Iaccarino L, Hasan SK, Mancini M, Divona M, Lavorgna S, Cicconi L, Panetta P, Maurillo L, Del Principe MI, Irno Consalvo M, Franceschini L, Angelini DF, Battistini L, Guerrera G, De Bardi M, Fabiani E, Falconi G, Arcese W, Amadori S, Buccisano F, Venditti A, Voso MT, Lo-Coco F.

Am J Hematol. 2018 May;93(5):E120-E123. doi: 10.1002/ajh.25061. Epub 2018 Feb 24. No abstract available.

14.

Osteoinductivity of nanostructured hydroxyapatite-functionalized gelatin modulated by human and endogenous mesenchymal stromal cells.

Della Bella E, Parrilli A, Bigi A, Panzavolta S, Amadori S, Giavaresi G, Martini L, Borsari V, Fini M.

J Biomed Mater Res A. 2018 Apr;106(4):914-923. doi: 10.1002/jbm.a.36295. Epub 2017 Nov 27.

PMID:
29143449
15.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

16.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

17.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Forghieri F, Bigliardi S, Quadrelli C, Morselli M, Potenza L, Paolini A, Colaci E, Barozzi P, Zucchini P, Riva G, Vallerini D, Lagreca I, Marasca R, Narni F, Venditti A, Martelli MP, Falini B, Lo Coco F, Amadori S, Luppi M.

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. eCollection 2016 Dec.

18.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
19.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

20.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

21.

Secondary Cleft Lip Reconstruction and the Use of Pedicled, Deepithelialized Scar Tissue.

Nadjmi N, Amadori S, Van de Casteele E.

Plast Reconstr Surg Glob Open. 2016 Oct 25;4(10):e1061. eCollection 2016 Oct.

22.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F.

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27. No abstract available.

23.

Gelatin Porous Scaffolds as Delivery Systems of Calcium Alendronate.

Panzavolta S, Torricelli P, Casolari S, Parrilli A, Amadori S, Fini M, Bigi A.

Macromol Biosci. 2017 Mar;17(3). doi: 10.1002/mabi.201600272. Epub 2016 Oct 17.

PMID:
27748576
24.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.

25.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
26.

The optimal dosing of gemtuzumab ozagamicin: where to go from here?

de Witte T, Amadori S.

Haematologica. 2016 Jun;101(6):653-4. doi: 10.3324/haematol.2016.145763. Epub 2016 May 31. No abstract available.

27.

PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F.

Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2.

PMID:
27133819
28.

A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.

Del Principe MI, Sarmati L, Cefalo M, Fontana C, De Santis G, Buccisano F, Maurillo L, De Bellis E, Postorino M, Sconocchia G, Del Poeta G, Sanguinetti M, Amadori S, Pagano L, Venditti A.

Mycoses. 2016 Sep;59(9):594-601. doi: 10.1111/myc.12508. Epub 2016 Apr 8. Review.

PMID:
27061932
29.

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2016 Feb 5;6:20743. doi: 10.1038/srep20743. No abstract available.

30.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

31.

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2015 Dec 17;5:18137. doi: 10.1038/srep18137. Erratum in: Sci Rep. 2016;6:20743.

32.

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage.

Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G.

Oncotarget. 2016 Jan 12;7(2):2070-9. doi: 10.18632/oncotarget.6529.

33.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

34.

A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy.

Postorino M, Pupo L, Provenzano I, Del Principe MI, Buccisano F, Franceschini L, Rizzo M, Nasso D, Meconi F, Onnis I, Vaccarini S, Zizzari A, Anemona L, Mauramati S, Bruno E, Cantonetti M, Amadori S.

Ann Hematol. 2016 Jan;95(1):153-154. doi: 10.1007/s00277-015-2503-z. Epub 2015 Oct 7. No abstract available.

PMID:
26442854
35.

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).

de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F.

Ann Hematol. 2015 Dec;94(12):1981-9. doi: 10.1007/s00277-015-2486-9. Epub 2015 Sep 26.

36.

Biological monitoring of Italian soldiers deployed in Iraq. Results of the SIGNUM project.

Bolognesi C, Migliore L, Lista F, Caroli S, Patriarca M, De Angelis R, Capocaccia R, Amadori S, Pulliero A, Balia C, Colognato R, La Gioia V, Bonassi S, Izzotti A.

Int J Hyg Environ Health. 2016 Jan;219(1):24-32. doi: 10.1016/j.ijheh.2015.08.001. Epub 2015 Aug 4.

PMID:
26306831
37.

Multi-Layered Scaffolds for Osteochondral Tissue Engineering: In Vitro Response of Co-Cultured Human Mesenchymal Stem Cells.

Amadori S, Torricelli P, Panzavolta S, Parrilli A, Fini M, Bigi A.

Macromol Biosci. 2015 Nov;15(11):1535-45. doi: 10.1002/mabi.201500165. Epub 2015 Jun 30.

PMID:
26126665
38.

Congenital Ulcerated Lip Hemangioma Treated With a Cleft Lip Technique.

Bianchi A, Amadori S, Bassi M, Neri I, Campobassi A, Marchetti C.

Cleft Palate Craniofac J. 2017 Mar;54(2):231-234. doi: 10.1597/15-102. Epub 2015 Jun 29.

PMID:
26120886
39.

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.

Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F.

Clin Cancer Res. 2015 Sep 1;21(17):3977-85. doi: 10.1158/1078-0432.CCR-14-3186. Epub 2015 May 8.

40.

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14.

PMID:
25869029
41.

(90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.

Fabbri C, Bartolomei M, Mattone V, Casi M, De Lauro F, Bartolini N, Gentili G, Amadori S, Agostini M, Sarti G.

Cancer Biother Radiopharm. 2015 Jun;30(5):200-10. doi: 10.1089/cbr.2015.1819. Epub 2015 Apr 10.

PMID:
25860616
42.

Highly Porous Gelatin Reinforced 3D Scaffolds for Articular Cartilage Regeneration.

Amadori S, Torricelli P, Panzavolta S, Parrilli A, Fini M, Bigi A.

Macromol Biosci. 2015 Jul;15(7):941-52. doi: 10.1002/mabi.201500014. Epub 2015 Mar 19.

PMID:
25787871
43.

Effect of sterilization and crosslinking on gelatin films.

Amadori S, Torricelli P, Rubini K, Fini M, Panzavolta S, Bigi A.

J Mater Sci Mater Med. 2015 Feb;26(2):69. doi: 10.1007/s10856-015-5396-4. Epub 2015 Jan 29.

PMID:
25631265
44.

Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.

Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075. eCollection 2014. Review.

45.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

46.

Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24.

47.

Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.

Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F.

J Clin Oncol. 2014 Oct 20;32(30):3406-12. doi: 10.1200/JCO.2014.55.3453. Epub 2014 Sep 22.

PMID:
25245446
48.

Advances in the treatment of elderly and frail patients with acute myeloid leukemia.

Amadori S, Del Principe MI, Venditti A.

Curr Opin Oncol. 2014 Nov;26(6):663-9. doi: 10.1097/CCO.0000000000000124. Review.

PMID:
25162330
49.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
50.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29.

PMID:
24994606

Supplemental Content

Loading ...
Support Center